Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : NTRX-07
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Cleveland Clinic
Deal Size : $12.3 million
Deal Type : Series B Financing
NeuroTherapia Raises $12.3M in the First Close of its Series B Financing
Details : NeuroTherapia will use this funding primarily for the continued clinical development of NTRX-07, an orally available cannabinoid receptor agonist, for the treatment of Alzheimer's disease
Brand Name : NTRX-07
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 06, 2024
Lead Product(s) : NTRX-07
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Cleveland Clinic
Deal Size : $12.3 million
Deal Type : Series B Financing
NeuroTherapia Receives Grant from Alzheimer's Association for its Alzheimer’s Drug
Details : The net proceeds will be used for the development of its first-in-class drug, NTRX-07, a novel drug that targets neuroinflammation, for the treatment of Alzheimer's disease.
Brand Name : NTRX-07
Molecule Type : Small molecule
Upfront Cash : Undisclosed
May 08, 2024
NeuroTherapia Closes $8.8M Series A Financing Led By Brain Trust Accelerator Fund II
Details : NeuroTherapia is currently completing its first-in-human clinical trial using NTRX-07 with funding provided in part by a grant from the Alzheimer's Association. The company will use the Series A funds to finish this work while also undertaking a number o...
Brand Name : NTRX-07
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 22, 2020
LOOKING FOR A SUPPLIER?
Reset All
